Gaithersburg, Maryland – December 19, 2018: MaxCyte announced today that Debra K. Bowes, Chief Business Officer, CARMA™ Cell Therapy, and Claudio Dansky Ullmann, MD, Chief Medical Officer, will present on the company’s CARMA platform at two upcoming industry conferences: the Biotech Showcase in San Francisco and the Phacilitate Leaders World/World Stem Cell Summit 2019 in Miami. During the presentations, Ms. Bowes and Dr. Dansky Ullmann will discuss MaxCyte’s next-generation autologous CAR (chimeric antigen receptor) therapies and highlight how MaxCyte’s breakthrough CARMA platform in immuno-oncology allows for a rapid manufacture of CARs with transient expression that will allow timely delivery back to patients, and may potentially mitigate off-tumor toxicity enabling repeat dosing to patients.
Details for the presentations are as follows:
- January 8, 2019, 2 p.m. PT: Ms. Bowes will present “Novel mRNA-based Autologous CAR Therapies in Oncology” on day two of the Biotech ShowaseTM, which takes place at the Hilton San Francisco Union Square.
- January 24 at 11:50 a.m. ET: Dr. Dansky Ullmann will present at Phacilitate on “A Novel mRNA-Based CAR Therapy, Advancing CARs for Solid Tumors and Beyond” during the “Changing cancer treatment forever: Innovation in autologous cellular immunotherapies” session. This meeting takes place at the Hyatt Regency in Miami.
“We have two exciting opportunities to discuss the progress we’ve made with our CARMA platform and its potential in a broad range of targets and cancers, including solid tumors,” said Dr. Dansky Ullmann. “Our novel CAR construct is engineered with the intention of reducing potential adverse effects that have been evident with previous CAR technologies while allowing for multiple dosing. As our first clinical study of our first wholly-owned lead CAR therapeutic candidate MCY-M11 is ongoing, the innovative aspects of the platform are especially significant.”
Investigators are currently evaluating the safety and effectiveness of intraperitoneal infusions of MCY-M11 in a multi-center, non-randomized, open label, dose-escalation Phase I clinical trial in individuals with ovarian cancer and peritoneal mesothelioma. More information about the study can be found at ClinicalTrials.gov.
MaxCyte is a global cell-based medicines and life sciences company applying its patented cell engineering technology to help patients with high unmet medical needs in a broad range of conditions. MaxCyte is developing novel CARMA therapies for its own pipeline. CARMA is MaxCyte’s mRNA-based proprietary platform for autologous cell therapy. In addition, through its core business, the Company leverages its Flow Electroporation® Technology platform to enable its biopharmaceutical industry partners to advance the development of innovative, cutting-edge medicines, particularly in cell therapy, including the use of gene editing tools in the treatment of inherited genetic diseases and immuno-oncology approaches to treating cancer. The Company has placed its cutting-edge flow electroporation instruments worldwide, including with nine of the top ten global biopharmaceutical companies, and has more than 55 partnered program licenses in cell therapy including more than 25 licensed for clinical use. With its robust delivery technology, MaxCyte helps its partners to unlock the full potential of their products. For more information, visit www.maxcyte.com
For further information, please contact:
|Doug Doerfler, Chief Executive Officer||+1 301 944 1660|
|Claudio Dansky Ullmann, Chief Medical Officer|
|Claudia Dansky Ulmann, MD, Chief Medical Officer|
|Debra Bowes, Chief Business Officer|
|CARMA Cell Therapy|
|US Media Relations|
|Jamie Lacey-Moreira||+1 410 299 3310|